Lenalidomide (LEN) is increasingly being used for the treatment of multiple myeloma. Adverse cutaneous reactions to LEN are common and present almost exclusively within one month of initiating therapy. We report a case of delayed-onset LEN-associated eruption presenting over three years after starting treatment. Histopathologic findings are also described, which are infrequently reported for LEN-associated eruptions. Our case serves as a reminder that proper recognition and management of LEN-associated eruption is important in the treatment of multiple myeloma. Dermatologists should be aware of the potential for delayed presentations of adverse cutaneous reactions to LEN, even years after initiation.
|Original language||English (US)|
|Journal||Dermatology Online Journal|
|State||Published - 2021|
Bibliographical notePublisher Copyright:
Copyright 2021 by the author(s).
PubMed: MeSH publication types
- Case Reports
- Journal Article